Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
复制标题
在诊断性乳腺癌血清中评估已知的Oncoantibodies HER2，P53和Cyclin B1。
DOI：
10.1158/1940-6207.capr-11-0558
复制
发表时间：
2012-08
期刊：
影响因子：
--
通讯作者：
Disis ML
中科院分区：
文献类型：
--
作者：
Lu H;Ladd J;Feng Z;Wu M;Goodell V;Pitteri SJ;Li CI;Prentice R;Hanash SM;Disis ML
针对致癌蛋白的血清自身抗体在乳腺癌患者的血清中经常被检测到。目前尚不清楚在已确诊疾病的患者中鉴定的血清抗体是否也可以在新诊断疾病的患者中检测到，甚至在乳腺癌诊断之前也可以检测到。本研究使用治疗时、诊断时或诊断前收集的血清，旨在解决乳腺癌发展与血清抗体反应之间的时间关系。从针对八种已知乳腺癌抗原的血清抗体开始，我们首先鉴定了四种血清抗体，HER-2/neu、p53、CEA和细胞周期蛋白B1，它们在治疗时从乳腺癌患者收集的血清中显著增加。这些抗体在诊断时收集的乳腺癌血清中也升高。最后，在乳腺癌发生前和对照组中对来自女性的诊断前样本中的抗体反应进行比较，证明可以在乳腺癌诊断前平均超过150天收集的血清中检测到HER-2/neu和p53抗体。这些结果表明，血清自身抗体通常报告的血清中已建立的疾病患者的血清中也可以在诊断前血清中检测到，并可能是有用的乳腺癌的早期检测。
Serum autoantibodies, directed against oncogenic proteins, have been frequently detected in the sera of breast cancer patients. It is unknown whether serum antibodies that are identified in patients with established disease could also be detected in patients with newly diagnosed disease or even predate the diagnosis of breast cancer. Using sera collected at the time of treatment, at the time of diagnosis, or prior to the time of diagnosis, the current study aimed to address the temporal relationship between breast cancer development and serum antibody response. Starting from serum antibodies to eight known breast cancer antigens, we first identified four serum antibodies, HER-2/neu, p53, CEA, and cyclin B1, which are significantly increased in the sera collected from breast cancer patients at the time of treatment. These antibodies were also elevated in breast cancer sera collected at the time of diagnosis. Lastly, comparison of antibody responses in pre-diagnostic samples from women prior to the development of breast cancer and in controls demonstrated that antibodies to the HER-2/neu and p53 can be detected in sera that were collected on average more than 150 days before a breast cancer diagnosis. These results demonstrated that serum autoantibodies commonly reported in sera from patients with established disease can also be detected in pre-diagnostic sera and may be useful for the early detection of breast cancer.